SN	Job Title	Closing Date and Time	Details
1	The imperative for increased investment for an HIV cure	The imperative for increased investment for an HIV cure	The imperative for increased investment for an HIV cure
2	Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial	Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial	Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial
3	The Association of Mild Kidney Disease with Coronary Artery Disease Is Stronger for People Living With HIV	The Association of Mild Kidney Disease with Coronary Artery Disease Is Stronger for People Living With HIV	The Association of Mild Kidney Disease with Coronary Artery Disease Is Stronger for People Living With HIV
4	Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): a randomised, open-label, non-inferiority, 96-week trialevaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen (CAB/RPV) compared to daily oral therapy (DTG based TDF or TAF with 3TC or FTC backbone) in virologically suppressed adolescents living with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa	Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): a randomised, open-label, non-inferiority, 96-week trialevaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen (CAB/RPV) compared to daily oral therapy (DTG based TDF or TAF with 3TC or FTC backbone) in virologically suppressed adolescents living with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa	Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): a randomised, open-label, non-inferiority, 96-week trialevaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen (CAB/RPV) compared to daily oral therapy (DTG based TDF or TAF with 3TC or FTC backbone) in virologically suppressed adolescents living with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa
5	Weight Gain, Body Composition and Metabolic Parameters on Dolutegravir-Based Antiretroviral Therapy Versus Standard of Care in Children and Adolescents: A Secondary Analysis of the ODYSSEY Trial	Weight Gain, Body Composition and Metabolic Parameters on Dolutegravir-Based Antiretroviral Therapy Versus Standard of Care in Children and Adolescents: A Secondary Analysis of the ODYSSEY Trial	Weight Gain, Body Composition and Metabolic Parameters on Dolutegravir-Based Antiretroviral Therapy Versus Standard of Care in Children and Adolescents: A Secondary Analysis of the ODYSSEY Trial
6	BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20 years in sub-Saharan Africa	BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20 years in sub-Saharan Africa	BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20 years in sub-Saharan Africa
7	Short-cycle therapy (weekends-off) on dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a randomised, open-label, 96-week non-inferiority trial	Short-cycle therapy (weekends-off) on dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a randomised, open-label, 96-week non-inferiority trial	Short-cycle therapy (weekends-off) on dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a randomised, open-label, 96-week non-inferiority trial
8	Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial	Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial	Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial
9	Model-based evaluation of the interaction between ritonavirboosted atazanavir and rifampicin in Ugandan adults with HIV	Model-based evaluation of the interaction between ritonavirboosted atazanavir and rifampicin in Ugandan adults with HIV	Model-based evaluation of the interaction between ritonavirboosted atazanavir and rifampicin in Ugandan adults with HIV
10	Expanding access to long-acting HIV therapy in low-income and middle-income countries	Expanding access to long-acting HIV therapy in low-income and middle-income countries	Expanding access to long-acting HIV therapy in low-income and middle-income countries
11	Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa	Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa	Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa
12	Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study	Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study	Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study
13	Pharmacokinetics, Safety and Antiviral Activity of Rilpivirine in Antiretroviral-naïve Children With HIV ≥6 to <12 Years Old	Pharmacokinetics, Safety and Antiviral Activity of Rilpivirine in Antiretroviral-naïve Children With HIV ≥6 to <12 Years Old	Pharmacokinetics, Safety and Antiviral Activity of Rilpivirine in Antiretroviral-naïve Children With HIV ≥6 to <12 Years Old
14	Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites	Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites	Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites
15	High prevalence of low-level viremia among infants initiated on antiretroviral drugs following mother-to-child transmission of HIV	High prevalence of low-level viremia among infants initiated on antiretroviral drugs following mother-to-child transmission of HIV	High prevalence of low-level viremia among infants initiated on antiretroviral drugs following mother-to-child transmission of HIV
16	Second-Line Antiretroviral Therapy for Children Living with HIV in Africa	Second-Line Antiretroviral Therapy for Children Living with HIV in Africa	Second-Line Antiretroviral Therapy for Children Living with HIV in Africa
17	Efficacy and safety of B/F/TAF in treatmentnaïve and virologically suppressed people with HIV≥50 years of age: integrated analysis from six phase 3 clinical trials	Efficacy and safety of B/F/TAF in treatmentnaïve and virologically suppressed people with HIV≥50 years of age: integrated analysis from six phase 3 clinical trials	Efficacy and safety of B/F/TAF in treatmentnaïve and virologically suppressed people with HIV≥50 years of age: integrated analysis from six phase 3 clinical trials
18	Objectively Measured Physical Activity among People with and without HIV in Uganda: Associations with Cardiovascular Risk and Coronary Artery Disease	Objectively Measured Physical Activity among People with and without HIV in Uganda: Associations with Cardiovascular Risk and Coronary Artery Disease	Objectively Measured Physical Activity among People with and without HIV in Uganda: Associations with Cardiovascular Risk and Coronary Artery Disease
19	Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries	Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries	Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries
20	Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial	Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial	Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
21	Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study	Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study	Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study
22	Safety and efficacy of iron supplementation with 3 months of daily ferrous sulphate in children living with HIV and mild-to-moderate anaemia in Uganda: a double-blind, randomised, placebo-controlled trial	Safety and efficacy of iron supplementation with 3 months of daily ferrous sulphate in children living with HIV and mild-to-moderate anaemia in Uganda: a double-blind, randomised, placebo-controlled trial	Safety and efficacy of iron supplementation with 3 months of daily ferrous sulphate in children living with HIV and mild-to-moderate anaemia in Uganda: a double-blind, randomised, placebo-controlled trial
23	Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial	Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial	Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial
24	Changes in the Lipidome Are Associated With Immune Activation and Subclinical Vascular Disease in Youth With Human Immunodeficiency Virus in Uganda	Changes in the Lipidome Are Associated With Immune Activation and Subclinical Vascular Disease in Youth With Human Immunodeficiency Virus in Uganda	Changes in the Lipidome Are Associated With Immune Activation and Subclinical Vascular Disease in Youth With Human Immunodeficiency Virus in Uganda
25	Consensus-driven target product profiles for curative sickle cell disease gene therapies	Consensus-driven target product profiles for curative sickle cell disease gene therapies	Consensus-driven target product profiles for curative sickle cell disease gene therapies
26	Facilitators and barriers to initiating and completing tuberculosis preventive treatment among children and adolescents living with HIV in Uganda: a qualitative study of adolescents, caretakers and health workers	Facilitators and barriers to initiating and completing tuberculosis preventive treatment among children and adolescents living with HIV in Uganda: a qualitative study of adolescents, caretakers and health workers	Facilitators and barriers to initiating and completing tuberculosis preventive treatment among children and adolescents living with HIV in Uganda: a qualitative study of adolescents, caretakers and health workers
27	A miniaturized wash-free microfluidic assay for electrical impedance-based assessment of red blood cell-mediated microvascular occlusion	A miniaturized wash-free microfluidic assay for electrical impedance-based assessment of red blood cell-mediated microvascular occlusion	A miniaturized wash-free microfluidic assay for electrical impedance-based assessment of red blood cell-mediated microvascular occlusion
28	…So that’s why we hide, we don’t want them to know’— challenges to antiretroviral therapy adherence in Kampala, Uganda	…So that’s why we hide, we don’t want them to know’— challenges to antiretroviral therapy adherence in Kampala, Uganda	…So that’s why we hide, we don’t want them to know’— challenges to antiretroviral therapy adherence in Kampala, Uganda
29	D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years	D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years	D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years
30	Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study	Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study	Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study